Blood Cancer Talks

Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
  • ٤٫٨ (٤٧)
  • تعليم
  • مرتان في الشهر
Blood Cancer Talks

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk

  1. قبل ٣ أيام

    Episode 55. ASH 2024 Myeloma Updates with Dr. Rakesh Popat

    In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed: 1. AQUILA Trial in High-Risk SMM Overview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring. Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara. Insights into modes of progression, adequacy of active surveillance, and post-protocol therapy in control arm. Read the abstract. Read the simultaneous publication at NEJM. 2. Anito-Cel: New BCMA CAR T Therapy  Early data from the iMMagine-1 trial showing strong efficacy and a promising safety profile for Anito-Cel, a novel BCMA CAR T. Discussion of its potential to rival cilta-cel while avoiding neurotoxicity concerns. Read the abstract.3. CARTITUDE-4 Update  Updates on MRD-negativity rates and survival outcomes for cilta-cel in relapsed myeloma, with significant benefits over standard care. Read the abstract.4. ANDROMEDA OS Data in AL Amyloidosis  Long-term data showing an overall survival (OS) benefit of Dara-VCd over VCd in AL amyloidosis. Insights into cardiac responses and crossover impact. Read the abstract.5. OPTIMUM Trial in Ultra-High-Risk NDMM Five-year follow-up of a tailored approach for ultra-high-risk newly diagnosed myeloma patients with continuous therapy incorporating multiple active agents. Subgroup outcomes highlighting both challenges and exceptional results. Read the abstract6. GMMG-HD7 Trial PFS Update  Phase 3 trial results on Isa-VRD vs. VRD induction and risk-adapted tandem ASCT. Discussion on the role of CD38 in maintenance therapy. Read the abstract Read the simultaneous publication at JCO7. Exciting New Drugs  Review of three innovative therapies: inobrodib, a BCMA-CD38 trispecific antibody, and cevostamab, a FcRH5-targeted bispecific antibody. Expert insights into their efficacy and potential to reshape myeloma care. Read the abstract

    ٣٨ من الدقائق

  2. ٢١‏/٠٦‏/١٤٤٦ هـ

    Episode 54. ASH 2024 Lymphoma and CLL Highlights

    In this episode, we discussed the top abstracts in lymphoma and CLL presented at the ASH 2024 annual meeting in San Diego with Dr. David A Russler-Germain from Washington University. Here are the key abstracts we discussed:  1. 3 RCTs in Mantle Cell Lymphoma:  a) Update on TRIANGLE: https://ash.confex.com/ash/2024/webprogram/Paper200735.html b) ENRICH Trial (Continuous Ibrutinib-Rituximab vs CIT [R-CHOP or BR]): https://ash.confex.com/ash/2024/webprogram/Paper199710.html c) ECOG-ACRIN EA4151 Trial (Auto-HCT vs Rituximab maintenance alone in patients with undetectable MRD after induction): https://ash.confex.com/ash/2024/webprogram/Paper212973.html 2. DLBCL:  a) Update on POLARIX Trial: https://ash.confex.com/ash/2024/webprogram/Paper197938.html b) Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in DLBCL Patients Receiving Polatuzumab Vedotin: https://ash.confex.com/ash/2024/webprogram/Paper202153.html c) COALITION trial: https://ash.confex.com/ash/2024/webprogram/Paper204930.html 3. Follicular Lymphoma:  a) Phase 3 inMIND trial (Tafasitamab + R2 vs Placebo + R2): https://ash.confex.com/ash/2024/webprogram/Paper212970.html b) Loncastuximab tesirine with rituximab in patients with R/R FL: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00345-4/abstract 4. CLL:  a) AMPLIFY Trial (Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy in 1st line CLL): https://ash.confex.com/ash/2024/webprogram/Paper200701.html 5. Hodgkin Lymphoma:  a) Pembrolizumab Maintenance Instead of Auto-HCT for R/R HL: https://ash.confex.com/ash/2024/webprogram/Paper202537.html

    ٥٨ من الدقائق

  3. ١١‏/٠٥‏/١٤٤٦ هـ

    Episode 53. Belantamab Makes a Comeback with Dr. Hang Quach

    In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed:  1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828933/ 2. DREAMM-8 RCT: Belantamab-Pd vs PVd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828951/ 3. Long-term follow-up of CASSIOPEIA Trial: https://pubmed.ncbi.nlm.nih.gov/38889735/ 4. Update on MRD data from PERSEUS Trial: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7502

    ٤٥ من الدقائق

  4. ٢٣‏/٠٤‏/١٤٤٦ هـ

    Episode 52. Management of Hodgkin Lymphoma in Older Adults with Dr. Andrew Evens

    In this episode, we dive into the management of older adults with Hodgkin Lymphoma with Dr. Andrew Evens. Here are the key articles we discussed: 1. Comparison of ABVD versus Stanford V in older Hodgkin Lymphoma patients: https://pmc.ncbi.nlm.nih.gov/articles/PMC3906856/ 2. Outcome of older adults ECHELON-1: https://pubmed.ncbi.nlm.nih.gov/34162178/ 3. Sequential BV-AVD in older adults with Hodgkin Lymphoma: https://pubmed.ncbi.nlm.nih.gov/30179569/ 4. SWOG S1826 trial (Nivo-AVD vs AAVD in advanced stage classical HL): https://pubmed.ncbi.nlm.nih.gov/39413375/ 5. S1826 outcomes in older adults: https://ash.confex.com/ash/2023/webprogram/Paper180114.html 6. Single-agent BV for older adults with Hodgkin: https://ashpublications.org/blood/article/142/Supplement%201/4435/503453

    ٤٢ من الدقائق

  5. ٢٤‏/٠٣‏/١٤٤٦ هـ

    Episode 51. Venetoclax in AML with Dr. Andrew Wei

    In this episode, we discuss the history of venetoclax in AML, along with key clinical trials that have shaped its current use in AML. Here are the trials discussed in this episode:  1. VIALE-A study: https://www.nejm.org/doi/full/10.1056/NEJMoa2012971 2. 10 day Decitabine plus venetoclax for ND AML https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30210-6/abstract 3. Genetic Risk Stratification and Outcomes with AML treated with venetoclax and azacitidine https://ashpublications-org.proxy.library.vanderbilt.edu/blood/article/doi/10.1182/blood.2024024944/517355/Genetic-Risk-Stratification-and-Outcomes-Among 4. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations https://ashpublications-org.proxy.library.vanderbilt.edu/blood/article/doi/10.1182/blood.2024025409/517356/Genetic-risk-classification-for-adults-with-AML 5. AGILE study: Ivosidenib and azacitidine in IDH1-mutated AML https://www.nejm.org/doi/full/10.1056/NEJMoa2117344 6. MRD response and prognosis in treatment naïve AML with AZA/VEN https://ascopubs.org/doi/10.1200/JCO.21.01546?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 7. Monocytic subclone confer resistance to venetoclax-based therapy in patients with AML https://aacrjournals.org/cancerdiscovery/article/10/4/536/2403/Monocytic-Subclones-Confer-Resistance-to 8. VEN/DEC vs 7+3 https://ashpublications.org/blood/article/142/Supplement%201/970/503790/Comparing-the-Efficacy-and-Safety-of-Venetoclax 9. FILO study: Outcomes of AML  https://onlinelibrary.wiley.com/doi/10.1002/ajh.27417 10. Treatment-free remission after ceasing venetoclax-based therapy in patients with AML https://ashpublications-org.proxy.library.vanderbilt.edu/bloodadvances/article/6/13/3879/485175/Treatment-free-remission-after-ceasing-venetoclax 11. Targeting molecular MRD and low-blast relapse in AML with Venetoclax and LDAC (VALDAC) https://ascopubs-org.proxy.library.vanderbilt.edu/doi/10.1200/JCO.23.01599?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 12. INTERCEPT trial: https://ashpublications.org/blood/article/140/Supplement%201/3341/492722/ALLG-AMLM26-Phase-1B-2-Study-Investigating-Novel

    ٥٧ من الدقائق

  6. ٢٥‏/٠٢‏/١٤٤٦ هـ

    Episode 50. Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma with Dr. Timothy Schmidt

    In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space.  Here are the key papers we discussed:  1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/34655533/ 2. S0777 trial (VRd vs Rd in newly diagnosed myeloma [transplant-ineligible or transplant-deferred]): https://pubmed.ncbi.nlm.nih.gov/32393732/ 3. IMROZ trial (Isatuximab-VRd vs VRd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38832972/ 4. IFM-2020/BENEFIT trial (Isatuximab-VRd vs Isatuximab-Rd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38830994/ 5. GEM2017FIT trial (VMP-Rd vs KRd vs Dara-KRd in newly diagnosed transplant-ineligible myeloma): https://ashpublications.org/blood/article/142/Supplement%201/209/500199

    ٤٢ من الدقائق

  7. ١٠‏/٠٢‏/١٤٤٦ هـ

    Episode 49. Updates on Low-Risk MDS with Dr. Maximilian Stahl

    In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteria https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/  2. MEDALIST trial: Luspatercept https://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed  3. COMMANDS trial : Luspatercept  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00874-7/abstract https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00203-5/abstract  4. IMerge trial: Imetelstat  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract

    ٤٣ من الدقائق

  8. ١٥‏/٠١‏/١٤٤٦ هـ

    Episode 48. Management of Polycythemia Vera with Dr. Aaron Gerds

    In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed:  1.     MIPS PV scoring system https://pubmed.ncbi.nlm.nih.gov/31945802/ 2.     REVEAL study https://ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell 3.     MAJIC PV study https://ascopubs.org/doi/10.1200/JCO.22.01935?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 4.     Cyto-PV Study https://www.nejm.org/doi/full/10.1056/NEJMoa1208500 5.     PROUD-PV and CONTINUATION-PV trials https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30236-4/abstract 6.     RESPONSE clinical trial https://www.nejm.org/doi/full/10.1056/NEJMoa1409002 7.     Rusferitide in PV https://www.nejm.org/doi/10.1056/NEJMoa2308809?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

    ٥٧ من الدقائق
مشاهدة الكل (٥٦)

مقطع ترويجي

٤٫٨
من ٥
‫٤٧ من التقييمات‬

حول

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk

المعلومات

  • صناع العمل
    Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
  • سنوات النشاط
    ١٤٤٣ هـ - ١٤٤٦ هـ
  • الحلقات
    ٥٦
  • التقييم
    ملائم
  • حقوق النشر
    © 2025 Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

قد يعجبك أيضًا

  • Two Onc Docs
    طب
    طب

    يتم التحديث أسبوعيًا

  • غير لائق، WolverHeme Happy Hour
    طب
    طب

    يتم التحديث شهريًا

  • Blood Podcast
    العلوم
    العلوم

    يتم التحديث أسبوعيًا

  • VJHemOnc Podcast
    طب
    طب

    يتم التحديث شهريًا

  • NEJM This Week
    طب
    طب

    يتم التحديث أسبوعيًا

  • Treating Blood Cancers
    طب
    طب

    مرتان في الشهر

  • EHA Unplugged
    تعليم
    تعليم

    يتم التحديث أسبوعيًا

للاستماع إلى حلقات ذات محتوى فاضح، قم بتسجيل الدخول.

اطلع على آخر مستجدات هذا البرنامج

قم بتسجيل الدخول أو التسجيل لمتابعة البرامج وحفظ الحلقات والحصول على آخر التحديثات.
تحديد بلد أو منطقة

أفريقيا والشرق الأوسط، والهند

آسيا والمحيط الهادئ

أوروبا

أمريكا اللاتينية والكاريبي

الولايات المتحدة وكندا